Kuros Biosciences Treats First Patient in Clinical Trial of MagnetOs Putty

Kuros Biosciences MagnetOs

Kuros Biosciences treated the first patient in a prospectively designed, randomized controlled U.S. trial named PROOF, comparing MagnetOs Putty to autograft for posterolateral spine fusion.

This Level 1 quality trial will be the first such U.S. clinical study of MagnetOs for spinal fusion. The putty will be implanted on one side of the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us